Q3 2024 Management View Revenue for Q3 FY2024 increased 16.6% year-on-year to ¥1,367.6 billion, driven by growth in oncology ...

Roche is the recipient of the new approval, getting the go-ahead from the US regulator for its PATHWAY HER2 (4B5) test to ...

Seagen hailed the outcome of the lawsuit, saying it will now seek royalties on all future US sales of Enhertu through the remaining lifespan of the patent, which expires in November 2024.

智通财经app获悉，1月27日，第一三共与阿斯利康(azn.us)宣布enhertu（德曲妥珠单抗）的补充生物制品许可申请（sbla）获fda批准，用于单药治疗在转移性 ...

12月5日，中国国家药监局药品审评中心（CDE）官网新公示显示，由阿斯利康（AstraZeneca）申报的AZD2936和DS-8201a两款新药同时获得临床试验默示许可，适应症为局部晚期或转移性HER2表达胆道癌患者的一线治疗。 公开资料显示，DS-8201a（即注射用德曲妥珠单抗，Enhertu ...

FDA approves Enhertu for metastatic breast cancer with HER2-low or HER2-ultralow expression after showing significant ...

AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has received approval from ...

Sales of Enhertu in the US are recognised by Daiichi Sankyo. AstraZeneca reports its share of gross profit margin from Enhertu sales in the US as Alliance Revenue in the Company's financial ...

In the HER2-low population, treatment with trastuzumab deruxtecan reduced the risk of disease progression or death by 38% compared with chemotherapy. The Food and Drug Administration (FDA) has ...

AstraZeneca AZN and partner Daiichi Sankyo announced that the FDA has approved the supplemental biologics license application (sBLA) seeking approval for expanded use of Enhertu (trastuzumab ...

Enhertu (fam-trastuzumab deruxtecan-nxki) can cause side effects that range from mild to serious. More common side effects include hair loss, nausea, and vomiting. If Enhertu side effects become ...